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Therapy of X-linked adrenoleukodystrophy
Abstract
X-linked adrenoleukodystrophy (X-ALD; OMIM #300100) is caused by defects of the ABCD1 gene on
chromosome Xq28, resulting in an impairment of peroxisomal beta-oxidation and the accumulation of
saturated very long chain fatty acids (VLCFAs). Primary manifestations occur in the CNS, the adrenal
cortex and the testes' Leydig cells. The clinical presentation shows a marked variability which is not
explained by the different X-ALD genotypes. Phenotypes range from rapidly progressive cerebral
disease with childhood (childhood cerebral ALD [CCALD]) or adulthood (adult cerebral ALD
[ACALD]) onset leading to death within a few years, over adult-onset adrenomyeloneuropathy (AMN)
with or without focal CNS demyelination, AMN converting into a rapidly progressive, cerebral
demyelinating phenotype resembling CCALD, to slow disease progression over decades, or adrenal
insufficiency only. Approximately 50% of female heterozygotes develop moderate spastic paresis
resembling the AMN phenotype. This review focuses on current experiences with different therapeutic
approaches. Lorenzo's oil did not prove to be effective in cerebral inflammatory disease variants, but
asymptomatic patients, and speculatively AMN variants without cerebral involvement, as well as female
carriers may benefit from early intake of oleic and erucic acids in addition to VLCFA restriction.
Hormone-replacement therapy is necessary in all patients with adrenal insufficiency. Hematopoietic
stem cell transplantation has been reported to be effective in presymptomatic or early symptomatic
CCALD, and may well also be a final therapeutic option in early ACALD patients. Early detection of
mutation carriers and timely initiation of therapy is important for the effectiveness of all therapeutic
efforts. Gene therapy of endogenous hematopoietic stem cells, pharmacological upregulation of other
genes encoding proteins involved in peroxisomal beta-oxidation, reduction of oxidative stress, and
possibly lovastatin are candidates for future X-ALD therapies.
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Therapy of X-linked Adrenoleukodystrophy 
 
Abstract 
X-linked adrenoleukodystrophy (X-ALD, OMIM #300100) is caused by defects of the ABCD1 gene on 
chromosome Xq28 resulting in an impairment of peroxisomal beta-oxidation and the accumulation of 
saturated very long chain fatty acids (VLCFA). 
Primary manifestations occur in the central nervous system (CNS), the adrenal cortex and the testes’ 
Leydig cells. The clinical presentation shows a marked variability which is not explained by the 
different X-ALD genotypes. Phenotypes range from rapidly progressive cerebral disease with 
childhood (CCALD) or adulthood (ACALD) onset leading to death within a few years, over adult onset 
adrenomyeloneuropathy (AMN) with or without focal CNS demyelination, AMN converting into a 
rapidly progressive, cerebral demyelinating phenotype resembling CCALD, to slow disease 
progression over decades or adrenal insufficiency only. About 50% of female heterozygotes develop 
moderate spastic paresis resembling the AMN phenotype. This review focuses on current 
experiences with different therapeutic approaches. Lorenzo’s oil did not proof to be effective in 
cerebral inflammatory disease variants, but asymptomatic patients, and speculatively AMN variants 
without cerebral involvement, as well as female carriers may benefit from early intake of such oleic 
and erucic acids in addition to VLCFA restriction. Hormone replacement therapy is necessary in all 
patients with adrenal insufficiency. Hematopoietic stem cell transplantation has been reported to be 
effective in presymptomatic or early symptomatic CCALD and may well be a final therapeutic option in 
early ACALD patients as well. Early detection of mutation carriers and timely initiation of therapy is 
important for the effectiveness of all therapeutic efforts. Gene therapy of endogenous hematopoietic 
stem cells, pharmacological up-regulation of other genes encoding proteins involved in peroxisomal 
beta-oxidation, reduction of oxidative stress, and possibly lovostatin are candidates for future X-ALD 
therapies.  
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pharmacological up-regulation of ABC transporters 
 
Background 
The pathologic first report of a patient with X-chromosomal linked adrenoleukodystrophy (X-ALD, 
OMIM 300100) was published by Siemerling and Creutzfeld in 1923. 50 years later Powers and 
Schaumburg [1] demonstrated characteristic inclusions in adrenal cortical cells (Fig 1C) and in brain 
macrophages, which were then identified as saturated very long chain fatty acids (VLCFA) by Igarashi 
et al. [2]. This led to the recognition that X-ALD is a metabolic disease and the identification of 
thousands of new patients with the various clinical phenotypes by the detection of increased VLCFA 
plasma levels [3-5]. X-linkage of this disease was first proposed on basis of a pedigree analysis by 
Fanconi et al 1963 [6]. In 1981 the X-ALD locus was mapped to chromosome Xq28 [7], and twelve 
years later, the X-ALD gene (ABCD1) was identified [8,9]. Today X-ALD has been identified in most 
countries worldwide and in most ethnic groups. The minimum frequency of hemizygotes in the United 
States was determined to be 1:42,000 and the one of hemizygotes plus heterozygotes 1:16,800, 
suggesting X-ALD as the most common inherited leukodystrophy [10].  
 
X-ALD phenotypes 
X-ALD is characterized by a highly variable clinical spectrum, from early progressive childhood to mild 
adulthood disease with only slow symptom progression over decades. The various phenotypes can 
occur within the same sibship [11,12]. Several phenotypes can be distinguished: 
 
Childhood cerebral ALD (CCALD) 24 
25 
26 
27 
Approximately, 35-40% of male X-ALD patients develop childhood cerebral ALD (CCALD) [11,13]. 
Onset of symptoms of this rapidly progressive cerebral form is usually in childhood (mean age 7 ± 2 
years). Less frequently, the first symptoms of rapidly progressive cerebral ALD occur in adolescence 
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(adolescent cerebral ALD) or in adulthood (ACALD). One case of ACALD with onset of disease at 57 
years of age after a CNS trauma exemplifies the discussion of triggering effects on onset of disease 
[14]. Initial neurological symptoms of CCALD may be behavioural changes, poor school performance, 
impaired auditory discrimination, or impaired visual acuity. Typically, symptoms become more severe 
within some months, and patients may present e.g. with progressive dementing illness, ataxia, visual 
and hearing loss and progressive spastic paraplegia. Most patients with CCALD are in a vegetative 
state or die within three years after onset of symptoms. Cerebral magnetic resonance imaging (MRI) 
typically reveals extensive demyelination with peripheral enhancement in the occipital (80%) or frontal 
(20%) periventricular white matter usually starting in the corpus callosum (Fig. 2A). The demyelination 
is accompanied by a vehement inflammatory reaction, which is characteristic for the rapidly 
progressive cerebral forms of ALD and associated with accumulation of lymphocytes, activation of 
microglia and expression of proinflammatory factors like tumor necrosis factor, interleukins and 
chemokines [15,16]. 
 
Adrenomyeloneuropathy (AMN)  15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
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AMN is seen in approximately 45% of male cases. Most frequently, onset of this milder phenotype is 
in the third to fifth decade (mean 28 ± 9 years). AMN usually is slowly progressive with initial 
symptoms limited to the spinal cord and peripheral nerves. Patients gradually develop a spastic 
paraparesis, often combined with impaired vibration sense, sphincter dysfunction and impotence. 
About 70% of AMN patients have adrenocortical insufficiency (Addison's disease) at the time when 
neurological symptoms are noted [11,13,17,18]. An equal percentage have signs of testicular 
insufficiency, occasionally even in the absence of other symptoms [19]. About 55% of AMN patients 
do not develop cerebral involvement (“pure” AMN), but in the remaining 45%, focal central nervous 
system demyelination evolves (spine or brain, adrenoleukomyeloneuropathy, ALMN). A retrospective 
study revealed that, over a period of 10 years, about 18% of AMN patients developed severe cerebral 
demyelination. These patients had a poor prognosis, although progression was somewhat slower 
than in CCALD [20]. 
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70% of all males with X-ALD have primary adrenocortical insufficiency (Addison’s disease). Primary 
adrenocortical insufficiency without evidence for nervous system involvement (‘Addison-only’ 
phenotype) is found in approximately 10% of male X-ALD patients. Signs of adrenal insufficiency may 
start between two years of age and adulthood, but most commonly they start between 5 and 10 years 
of age. Clinical manifestations include unexplained vomiting and weakness or coma, leading to the 
diagnosis of Addison’s disease. Individuals may have increased skin pigmentation resulting from 
excessive ACTH secretion. Most individuals who initially present with adrenocortical insufficiency 
develop AMN in the third or fourth decade [13].  
 
Presymptomatic carriers 12 
13 
14 
15 
16 
17 
18 
19 
Asymptomatic or presymptomatic male patients, mostly identified during family screenings at young 
age, may have neither neurological nor endocrinological abnormalities. Before the age of 
approximately 4 years this phenotype is common, but becomes rare in males older than 40. Even 
then, asymptomatic patients are still at high risk for developing neurological symptoms, and detailed 
investigation often shows subtle signs of adrenal hypofunction or AMN [11,13]. However, a few 
patients remain asymptomatic into their sixties [21]. 
 
Manifesting females 20 
21 
22 
23 
24 
25 
26 
27 
The majority of heterozygous women who are younger than 30 years are free from neurological 
symptoms. However, subtle signs of long spinal tract involvement may be detected in  
neurophysiological investigations [22]. Over the age of 40, approximately 50% of women present with 
mild to severe neurological signs, in particular myeloneuropathy manifesting with progressive spastic 
paraparesis, sensory deficits and bladder dysfunction [13]. MRI changes are usually not present or 
are non-specific [23]. Since symptoms in symptomatic heterozygotes and multifocal but unspecific 
MRI abnormalities in older heterozygotes may be similar to those found in multiple sclerosis of the 
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primary progressive type, female AMN is frequently misdiagnosed as multiple sclerosis [24], in 
particular in the absence of a positive family history or the presence of negative biochemical test 
results. Rarely, childhood onset, cognitive decline, visual disturbances, or olivopontocerebellar 
syndrome may be present in manifesting female carriers [25]. Also Addison’s disease is very rare, 
with a frequency of less than 1% at any age [11,13,23]. Plasma VLCFA are increased in most female 
carriers, but false negative or equivocal results occur in up to 20% of obligate heterozygotes, and 
normal plasma VLCFA levels thus do not exclude heterozygosity for X-ALD [5,26,27]. To minimize the 
risk of false-negative results, especially in view of preparing prenatal diagnostic procedures, mutation 
analysis is recommended in biochemically non-informative females [27,28].   
 
Rare manifestations 11 
12 
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Rare manifestations in adults include localized neurological signs such as hemiparesis, visual field 
defects, aphasia, signs of raised intracranial pressure, progressive behavioral disturbance and 
dementia, ataxia, neurogenic bladder and bowel abnormalities as well as impotence without other 
neurological or endocrine disturbances. Predominantly brain stem and cerebellar involvement 
resembling olivo-ponto-cerebellar atrophy is observed, frequently combined with severe cognitive 
deficits [29,30]. Additionally, optic atrophy has been described [25,31,32]. 
 
Biochemistry 
X-ALD is biochemically characterised by elevated plasma and tissue levels of VLCFA, particularly 
hexacosanoic (C26:0) and tetracosanoic (C24:0) acids. Increased VLCFA plasma levels are found in 
all male patients and most female heterozygotes and originate from both diet and endogenous 
synthesis. The high VLCFA content of brain, adrenal glands and testis is hypothesized to participate 
in the pathologic manifestations observed in these tissues and is therefore suspected to be a crucial 
factor in the pathogenesis of X-ALD. Lowering VLCFA levels is regarded an important therapeutic 
target. However, the exact mechanisms, how ABCD1 mutations lead to VCLFA accumulation and 
how VCLFA accumulation leads to these pathological manifestations, are unknown.  
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VLCFA are progressively degraded in a series of four enzymatic reactions by two carbon atoms at a 
time as they repeatedly cycle through ß-oxidation pathway in the peroxisomes. Before degradation 
VLCFA must be activated to their coenzyme-A thioesters in an ATP-dependent reaction catalyzed by 
a very long chain acyl-CoA synthetase (VLCS) [33]. In X-ALD the elevation of VLCFAs is associated 
with reduced ß-oxidation and reduced activity of VLCS [34,35]. 
But the adrenoleukodystrophy protein (ALDP), which is coded by the X-ALD gene ABCD1, does not 
have properties of β – oxidation or VLCS. ALDP belongs to the ATP-binding cassette (ABC) 
transporter superfamily. ALDP is an integral peroxisomal membrane protein with its ATP-binding 
domain located towards the cytosolic side of the peroxisomal membrane. The function of ALDP is 
unknown. It is suspected that ALDP is necessary for transferring VLCFA or VLCFA-CoA into the 
peroxisomes. However, a peroxisome membrane transporter function of ALDP could only be 
demonstrated in yeast, but not in mammalian cells, yet [36]. Furthermore, the elevation of VLCFA 
levels does not only result from impaired perioxisomal  β – oxidation, but also from enhanced VLCFA 
elongation in X-ALD. This is probably due to an additional effect of unchecked chain elongation and 
leads to increased concentrations of VLCFAs up to 32 carbons [37].  
Interestingly, an alternative method of VLCFA degradation was recently described. VLCFA can also 
be degraded by microsomal ω- oxidation followed by peroxisomal and/or mitochondrial β-oxidation of 
the dicarboxylic acids produced [38]. In fibroplasts from X-ALD patients dicarboxylic acids can 
undergo β-oxidation [39]. Accumulation of dicarboxylic acids has not been detected in X-ALD patients 
[40] indicating that ALDP is not implicated in the β-oxidation of dicarboxylic acids and that the 
microsomal VLCFA ω- oxidation forms a functional, yet not sufficiently effective pathway of 
normalization of VLCFA levels in X-ALD patients. If possible, stimulation of ω- oxidation may provide 
an alternative therapy of X-ALD. 
Also the role of VLCFA accumulation for pathological changes in tissues is unclear. It was suggested 
that inclusion of VLCFA into cell membranes disrupts membrane structure [41]. Recently, it was 
shown that elevated VLCFA are highly toxic to brain cells due to mitochondrial dysfunction [42] or 
impairment of oxidative stress homeostasis [43]. 
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Until now, the relationship between mutations in ABCD1, reduced peroxisomal β-oxidation, enhanced 
VCLFA elongation, microsomal ω- oxidation, increased levels of VLCFA and tissue alterations 
remains to be resolved. 
  
Genetics 
X-ALD is caused by defects of the ABCD1 gene. The ABCD1 gene is located on chromosome Xq28 
and contains ten exons encoding 745 amino acids [44]. Hitherto, 974 mutations have been identified 
in the ABCD1 gene, of which 485 are unique mutations (The X-ALD Database; www.x-ald.nl). Since 
the X-ALD phenotypic variety is not explained by the ABCD1 mutations, modifying factors like modifier 
genes and environmental factors have been discussed.  
 
Modifying factors 
The prognosis of an individual affected male cannot be predicted by biochemical factors like levels of 
VLCFA. In addition, no genotype/phenotype correlation could be established. Even within closely 
related patients, even within twins, the clinical course may range widely. Thus, yet unidentified 
modifier genes and other co-factors are likely to modulate the phenotypic variation, and disease 
severity [45-48]. Segregation analyses suggested that the phenotypic variability is, at least in part, 
due to an autosomal modifier gene [49,50]. Some authors suggested a 2-stage pathogenesis for the 
CCALD phenotype consisting of an initial CNS dysmyelination as a result of incorporation of VLCFA 
into myelin lipids followed by an inflammatory demyelinating process that may vary between 
individuals [15,16]. McGuiness et al detected higher tumor necrosis factor-alpha (TNF-alpha) 
bioactivity in advanced CCALD cases in comparison to AMN patients. These differences could not be 
explained by allelic diversity [51]. Others found that severity of the X-ALD phenotype is correlated with 
expression of an other peroxisomal transporter gene (ABCD4) and of the VLCFA synthase gene BG1 
[52]. Recently, we reported that functional polymorphisms of genes and proteins involved in 
methionine metabolism, which is important for cerebral myelination, inflammation and oxidative 
defense, were associated with the clinical course of X-ALD patients [53,54]. Unidentified 
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environmental factors may also be involved, as indicated by phenotypic variability in a set of 
monozygotic twins [55], and the disease may putatively also be triggered by CNS traumas [14]. 
Identification of X-ALD modifiers would be of relevance for prevention and therapeutic intervention. 
The possibility to predict whether an asymptomatic young boy is at high or low risk to develop CCALD 
would help to decide about hematopoietic stem cell transplantation (HSCT) for the prevention of 
CCALD (see below).  
 
Animal models 
Several animal models have been established. However, none is an exact phenocopy of human X-
ALD. Tissues from knockout (KO) mice lacking ABCD1 have a marked increase of VLCFA levels, but 
normal rates of β-oxidation [45,56]. These mice do not develop an inflammatory cerebral phenotype 
nor adrenal insufficiency like seen in human X-ALD [57-59]. Double KO mice deficient in ABCD1 and 
ABCD2 exhibit some inflammation, but no cerebral demyelination. The major lesion in these mice is 
spinal axonal degeneration typical for the adult-onset AMN [60,61]. 
In the brain, the majority of peroxisomes are associated with oligodendrocytes. Kassmann et al. 
recently developed a mouse model, which is a good copy of the human X-ALD phenotype and brain 
pathology by selective inactivation of the peroxin-5 (Pex5) gene in oligodendrocytes. Pex5, the 
peroxisomal targeting signal type-1 receptor, is a cytosolic receptor essential for protein import into 
the peroxisomal matrix [62]. PEX5 mutants have no deficits at birth, but develop a severe phenotype 
during later life including progressive ataxia, associated by VLCFA accumulation, progressive cerebral 
demyelination and neuroinflammation. As ABCD1 and PEX5 mutants show comparable increases of 
VLCFA levels in whole brain lysates (about fourfold elevation)[57-59,63], the inflammatory 
demyelination seen in PEX5 mutants is therefore unlikely to be a result of VLCFA accumulation alone. 
Speculatively, secondary as-yet-unidentified impairments in ABCD1-deficient peroxisomes, which 
become functional only over time and cannot be observed in short-lived mice, explain the phenotypic 
difference between PEX5 and ABCD1 mutants [63].   
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Diagnosis 
In boys, the typical initial symptoms, which should prompt evaluation for X-ALD, are behavioural 
changes, poor school performance, and impaired audio-visual discrimination. Within some months 
focal neurological signs and progressive dementing illness develop. Men usually present in their 
thirties or forties with slowly progressive symptoms limited to the spinal cord and peripheral nerves 
maybe combined with sphincter dysfunction and impotence. Special care should be taken in mild 
phenotypes and symptomatic females, as they are frequently misdiagnosed. All young men 
presenting with primary adrenal insufficiency have to be tested for X-ALD, as X-ALD without evidence 
for nervous system involvement (‘Addison-only phenotype’) is found in approximately 30% of male X-
ALD patients. 
Timely assays allow the detection of subtle increases in VLCFA levels in cultured fibroblasts, plasma, 
red blood cells, cultured chorion villus cells and amniocytes. These techniques permit precise pre- 
and postnatal diagnosis in males, the facilitation of genetic studies and gene mapping and the 
evaluation of therapeutic approaches. Increased plasma VLCFA levels in males confirm the diagnosis 
of X-ALD. Since plasma VLCFA levels may be normal in up to 20% of female heterozygotes, mutation 
analysis is necessary in female adrenoleukodystrophy [27,28]. 
A brain MRI should be performed to show confluent cerebral demyelinating lesions with peripheral 
enhancement typical for CCALD/ACALD and demyelinating foci which are observed in up to 50% of 
patients with AMN (Fig. 1 A, B; 2A) [21]. In addition, significant spinal cord atrophy and degeneration 
of long spinal cord tracts may be found by spinal cord MRI and neurophysiological studies (Fig. 2B). 
Evaluation of adrenal insufficiency (Addison's disease) is mandatory, commonly done by 
determination of aldosterone and cortisol levels and by an ACTH stimulation test, to decide whether 
hormone supplementation is needed. In addition, regular investigations by specialized physicians are 
advisable. Extended family screening helps to identify asymptomatic carriers, which have to be 
monitored closely and facilitates genetic counselling. 
 
Genetic counseling 
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X-ALD in males and affected females often is a disastrous illness for the patients and their families. In 
many cases more than one family member develops symptoms. Family screening aiming to identify 
members at risk and genetic counseling should be provided. The use of mutation analysis rather than 
VLCFA assays for the identification of women heterozygous for X-ALD is necessary [27,28]. Prenatal 
and preimplantation diagnoses by assays in cultured chorion villus cells and amniocytes are already 
available, but not legal in every country [64-66]. Given the increasing therapeutic options in X-ALD, 
newborn screening appears to be a sensible goal. 
 
Therapy 
A causal therapy of X-ALD is lacking. However, several studies have provided preliminary data about 
ALD therapy and a commonly accepted therapeutic approach, depending on the clinical situation, has 
been developed during the last decade. Currently used therapies of X-ALD include hormone 
replacement therapy, dietary therapy with Lorenzo’s Oil, and hematopoietic cell transplantation (HCT). 
Neuroinflammation seems to be an important pathomechanism at least in the cerebral forms of X-
ALD. However immunosuppression or immunomodulating therapies with cytoxan [67,68], β-interferon 
[69], intravenous immunoglobins [70], and modified cobratoxin [71] were ineffective. Although these 
studies are seriously hampered by very small patient samples and short treatment periodes, these 
results were not promising enough to encourage further clinical trials on immunomodulating therapies. 
New potential therapies like lovostatin, 4- phenylbuturate, gene therapy and antioxidants have been 
proposed recently and will be discussed in the section ‘Five-year view’. 
 
Adrenal insufficiency 22 
23 
24 
25 
26 
27 
Adrenal insufficiency manifests early and often before the onset of neurological symptoms. It has a 
high prevalence in otherwise asymptomatic boys with X-ALD and is a frequent cause of morbidity 
which can be prevented by careful monitoring and timely initiation of therapy [72]. In affected patients, 
adrenal hormone replacement therapy is mandatory and effective. Glucocorticoid requirements are 
similar as for other forms of adrenal insufficiency, ranging from 10 to 40mg glucocorticoid daily, 
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whereas mineralcorticoid replacement is not always necessary. When sickness or stress occurs, the 
dose has to be adapted to meet the increased demands. Hormone replacement therapy does not 
influence the development or progression of neurological symptoms [21]. 
 
Neurologically asymptomatic or presymptomatic patients 5 
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VLCFA accumulation, which is suspected to be a crucial factor in the pathogenesis of X-ALD, 
originates from both diet and endogenous synthesis [73,74]. In patients with X-ALD the ability to 
degrade VLCFA is impaired [35,74,75]. A pure restriction of VCLFA intake is insufficient to lower 
VLCFA levels [76]. In 1989 however, it was demonstrated that a 4:1 mixture of glycerol trioleate 
(GTO) and glyceryl trierucate (GTE), referred to as Lorenzo’s Oil (LO), can normalize the highly 
elevated concentrations of VLCFA in the plasma of boys with X-ALD, probably by competitive 
inhibition with the microsomal elongating system for saturated long chain fatty acids [77-80]. These 
studies raised the hope that LO intake in combination with a VLCFA-poor diet is beneficial in X-ALD. 
Recent reports from two independent concurrent treatment trials both demonstrated a preventive 
effect of LO on disease onset in asymptomatic boys with previously normal brain MRI [13,81,82]. A 
preventive, single-arm study without a placebo-group due to ethical reasons included 89 
asymptomatic patients (4.7±4.1 years of age), who were treated with LO and moderate fat restriction 
diet and who were followed up for 6.9±2.7 years. A significant association between the onset of MRI 
abnormalities, onset of neurological symptoms and the ability to normalize VLCFA plasma levels over 
time was reported [83]. This finding supports the hypothesis that VLCFA contribute to X-ALD 
pathology and are not only a biomarker of the disease. LO therapy is therefore strongly recommended 
for boys with X-ALD from the age of 1.5 years on who are neurologically asymptomatic and have 
normal MRI [13,84]. 
A standard dosage for initial LO treatment is 1ml/kg bodyweight. Plasma VLCFA levels should be 
monitored on a regular basis to meet the adequate LO dose. A practical goal seems to be a reduction 
of VLCFA to normal plasma levels. Possible side effects of LO are regularly moderate and include 
thrombocytopenia, anemia, leucopenia, increases in liver enzymes, gastrointestinal complaints and 
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gingivitis [85-90]. In addition to LO treatment a VCLFA-poor diet with fat restriction to 15% of the daily 
calories is applied. Parents should enlist the help of a dietician or nutritionist. A balanced diet is 
important for growth at this age, and essential fatty acids like docosahexaenoid acid and arachidonic 
acid are essential for brain and retinal development especially during the first year of life [91]. 
Dietary therapy does not improve endocrine function [87]. It is not clear how long LO therapy should 
be continued in patients who remain neurologically asymptomatic and continue to have normal 
cerebral MRI. Risk for CCALD is greatest for boys under the age of 7, decreases after the age of 10, 
and in particular after the age of 14 years, but never vanishes completely [13]. In addition, it is not 
known whether LO therapy delays onset of AMN in previously asymptomatic men. However, given the 
lack of other therapeutic agents, the authors feel that the already known results about LO therapy are 
sufficiently encouraging to warrant this therapy in all asymptomatic patients and neurodegenerative 
forms of X-ALD. However this recommendation is based on the personal experience of the authors 
and on preliminary data only [92](see also below). 
Timely initiation of LO therapy before onset of disease symptoms is essential and can only be 
provided by screening at-risk relatives of patients known to have ALD or of patients with Addison’s 
disease. Neonatal screening, however, would identify many more. Combined liquid chromatography-
tandem mass spectrometry for VLCFA should be a feasible method for high throughput newborn 
screening, but has to be established in larger series of samples [93]. The cost effectiveness of this 
measure has not been evaluated yet. 
Monitoring cerebral MRI is critically important in order to identify those patients who develop 
inflammatory brain disease and therefore have to be considered for timely therapy with bone marrow/ 
hematopoietic cell transplantation (HCT). It has been recommended that brain MRI should be 
obtained at 6 month intervals between 3 and 10 year old boys and yearly thereafter [13,83,94]. Brain 
involvement as detected by MRI may be visible far before clinical symptoms occur and it is important 
to remember that the therapeutic window for HCT may be already closed when they occur.  
 
Neurological symptomatic patients 27 
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Up to now HCT is the only treatment that has been proven to provide long-term benefit for boys and 
adolescents with early symptoms of cerebral inflammatory involvement based on clinical or MRI 
criteria. Timely treatment has stopped the degeneration in about 50% of the affected boys. However, 
it is a very risky procedure with mortality rates of 10-20% [94]. The exact mechanism of HCT in 
CCALD is not known. The rationale of the HCT relies on the hypothesis that fully functional, donated 
bone marrow cells can cross the blood brain barrier of the recipient and exert beneficial effects on the 
mechanisms leading to CNS demyelination. The first report about a favorable effect of HCT in a 
CCALD patient was published in 1990 [95] and several subsequent reports in small patients series 
showed positive results [96-100]. Follow-up studies demonstrated that the beneficial effect is 
maintained for 5-10 years [101,102]. The most comprehensive study by Peters et al. included 94 
patients [94]. Boys received bone marrow or umbilical cord cells from related or unrelated donors. The 
5 and 8 year survival probabilities were both 56%. In contrast, the survival at 5 years after 
presentation of CCALD without HCT is only 40% and almost 0% after 15 years (see Figure 3A) [11].  
More important, overall 5 year survival was associated with the severity of the phenotype and MRI 
abnormalities at the initiation of HCT. Neurologically asymptomatic boys (but with clear evidence of 
inflammatory brain disease in MRI) reached a 5-year survival of 93%, while moderately to severely 
affected boys had a 5-year survival of 44% (Figure 3B). Comparison with a historical series of 283 
CCALD patients without HCT therapy excluded the possibility that the favorable prognosis of not or 
mildly affected CCALD patients after HCT is attributable to a distinct phenotype category with a better 
prognosis even without HCT therapy. In addition, a significant difference in 5 years survival (95% in 
HCT versus 57% without HCT) and in the degree of disease progression (53% neurologically stable 
patients after HCT versus 6% stable patients without HCT) was found [103].  
HLA-mismatch also exerts an unfavorable effect on survival. The leading causes of death were 
progression of CCALD (60%) and graft versus host disease (GVHD) (14%). In the patients who were 
only mildly affected before HCT (n=58), 31 showed no disease progression. In the group with 
progression, a lower percentage of patients had full or partial donor derived engraftment (78%), in 
comparison to the group without progression (97%).  
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In the study of Peters et al. VLCFA levels were not collected. A smaller study monitored VLCFA 
before HCT and during follow-up and demonstrated a mean decrease of 55% within 2 years after 
HCT reaching mean VLCFA levels as found in heterozygotes [102]. The mechanism of the reduction 
of plasma VLCFA levels after HCT is unknown. It was not reported that the extent of the decrease of 
VLCFA plasma levels correlated with a better long-term neurological outcome or survival. Although 
the possible impact of additional lowering VLCFA levels by LO therapy is therefore questionable, the 
continuation of LO therapy before HCT is recommended by some authors, as they observed better 
outcomes after HCT in relation to pre-transplant VLCFA levels in their patients [104]. Visual 
dysfunction is a common component of the disease and may continue to progress in patients after 
HCT. Gess et al described factors, that correlate with loss of visual acuity after HCT (pretransplant 
MRI severity score, the presence of pretransplant parieto-occipital demyelination on MRI, and 
pretransplant IQ performance), which may help counseling patients considering HCT for X-ALD, as 
decisions about HCT in X-ALD rely upon prognostic information about adverse outcomes following 
HCT [105]. 
 
Based on the data currently available, HCT is not recommended for patients with AMN without 
cerebral involvement. Due to the slow rate of progression and the higher risk of GVHD in adults, the 
benefit-risk ratio is estimated to be unfavorable in AMN [94]. In AMN with early cerebral involvement 
or ACALD patients treatment experiences with HCT are very rare [106,107] indicating a favorable 
effect on survival rate, however, controlled clinical trials are missing. Therapeutic decision in these 
cases has to be based on individual assessment. 
 
Results from LO treatment in symptomatic patients are conflicting. A series of small clinical trials led 
to the conclusion that the intake of LO does not completely prevent the progression in all patients who 
are already neurologically symptomatic at initiation of the therapy [80,87-89,108], however, in the 
absence of any controlled studies, it is not possible to determine whether the reported progression in 
some symptomatic patients differs from what one would expect in untreated patients. Moreover, most 
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previous studies did not differentiate treatment effects between cerebral and non cerebral phenotypes 
which indeed would be crucial since the rapidity of disease progression and the pathogenetic 
background differs strongly. Finally, small study populations, short observation periods and poor 
treatment control in some of the studies led to inconclusive results. Preliminary results from a larger 
long-term follow-up study (mean treatment period 6,7 years) in 47 pure AMN patients treated with an 
initial dose of 1 ml/kg body weight LO and low VLCFA diet showed a reduction of disease progression 
in those patients, for whom normalization of VLCFA plasma levels could be achieved (n=45). In 
addition, occurrence of inflammatory demyelination seemed to be reduced or at least delayed, 
combined with an improvement of long-term prognosis [92]. While treatment of patients with cerebral 
inflammatory variants (CCALD, ACALD, AMN with cerebral involvement) did not proof effects, the 
normalization of VLCFA seem to be advisable in the more neurodegenerative forms of X-ALD (AMN, 
symptomatic heterozygotes, Addison’s disease only). However, this recommendation is the personal 
opinion and experience of the authors. Published clinical trials about the efficacy of LO therapy in 
symptomatic patients are missing up to date.  
 
Supportive Care 
Treatment following the diagnosis X-ALD requires a multi-disciplinary network adapted at the severity 
of the disease. Neuro-paediatricians or neurologists monitor the patients, prescribe drugs including 
LO, and treat spasms, seizures and other neurological symptoms of disease. The help of physical 
therapists is often required, and dieticians and speech therapists can provide support concerning 
occupation and loss of bulbar muscular function. Gastral tubes, tracheotomy and mechanical 
breathing support may become necessary. Social organisations can help to organize the daily life and 
school for affected children. For adult patients, urologic consultation due to decreased bladder control 
and erectile dysfunction may be necessary. Patients with the clinical presentation of hypogonadism, 
associated with low testosterone levels should receive androgens. Impotence is in most cases due to 
spinal cord degeneration or neuropathy rather than testosterone deficiency. Sildafenil has been 
shown to be effective in patients with spinal cord injury and can be considered for AMN-patients [109]. 
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AMN patients with cerebral involvement often require psychiatric consultation, as behavioural 
disturbances are frequent within this phenotype. Most commonly, these patients manifest signs of 
mania including dysinhibition, impulsivity, increased spending, hypersexuality, loudness, and 
perseveration [110,111]. Inappropriate behaviour may make commitment to a psychiatric facility 
and/or nursing home necessary.   
 
Expert Commentary 
For all established therapies of X-ALD, timely initiation and close monitoring is crucial. Individuals at 
risk for X-ALD should be identified at the earliest possible time point. Therefore, the screening of 
relatives of X-ALD patients is advisable. However, identification of all males with X-ALD by neonatal 
screening would have a much more profound impact for therapy and the therapeutic approach to this 
disorder. Monitoring of adrenal function and timely initiation of hormone replacement therapy is of 
crucial, often life saving importance. 
The data about efficacy of LO therapy in X-ALD phenotypes are hampered by the lack of a 
randomized placebo-trial. However, carefully supervised dietary therapy with Lorenzo’s oil seems to 
reduce the risk of developing CCALD and is recommended for all asymptomatic boys with X-ALD 
after the age of 1,5 years. Preliminary data from LO treated patients suggest a favorable modification 
of disease progression in AMN and symptomatic heterozygotes. A randomized placebo-controlled 
study is currently underway [112]. Given the serious nature of the disease, the lack of other 
therapeutic agents, and the finding that carefully monitored LO therapy can be performed without 
serious side effects and maintenance of normal daily activities, the already known results about LO 
therapy seem to be sufficiently encouraging to warrant this therapy in all asymptomatic patients and 
neurodegenerative forms (AMN, symptomatic heterozygotes, OPCA variants, Addison only, arrested 
cerebral variants) of X-ALD. This is the personal opinion and experience of the authors and is not 
based on robust published data.  
Treatment experiences with statins are currently not sufficiently valid enough for routine use. 
Regularly monitoring of neurological status and MRI in 6 months intervals until the age of 10 years, 
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and 1 year intervals thereafter, allows identifying patients developing cerebral inflammatory disease 
which then should be considered for HCT. HCT has a relevant chance of success when performed 
during this early stage of CCALD (and probably ACALD as well). The availability of a HLA-matched 
donor improves the outcome of the procedure. Promising candidates for future therapies of X-ALD are 
gene therapy strategies using endogenous hematopoietic stem cells and pharmacological up-
regulation of other ABC transporter proteins. 
 
Five-year view 
Although a therapeutic approach is available for X-ALD, only a smaller part of patients will clearly 
benefit from these therapies. Availability of HCT is often limited by the futile search of a well matched 
donor, and HCT holds many risks of complications. Therefore, alternative therapies for X-ALD are 
highly desirable.  
 
Induction of redundant genes 14 
15 
16 
17 
18 
19 
20 
21 
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Induction of redundant genes can compensate for the loss of ALDP by pharmacological up-regulation 
of other ABC transporter proteins. The peroxisomal membrane harbors – besides ALDP – three 
additional, closely related ABC transporters: ALDRP (encoded by ABCD2), PMP70 and PMP69, 
which have overlapping substrate specifities. ABCD2 expression can be enhanced by 
pharmacological agents like fibrates [34,61]. However, drugs to be identified suitable for 
pharmacological up-regulation of ALDRP and/or PMP70 have to be able to cross the blood brain 
barrier, which is not the case for many candidate drugs such as fenofibrate [113,114]. Other drugs like 
4-Phenylbutyrate pass the blood brain barrier in humans, but did not lead to decreased VLCFA levels 
in a small clinical trial with AMN patients and showed tachyphylaxis with VLCFA acid levels returning 
to pretreatment levels in a long-term study of X-ALD mice. If these problems could be solved, 
pharmacological up-regulation of other ABC transporter proteins seems to be a candidate mechanism 
for future therapies [34]. 
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Reduction of oxidative stress 1 
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Some authors propose that oxidative stress may be involved in the pathophysiology of X-ALD. An 
elevation of various oxidative stress parameters was shown in different tissues of X-ALD patients and 
ABCD1 knockout mice [115-117]. It is not clear, whether this oxidative damage is primary or 
secondary in the pathophysiological cascade, however this difference may be relatively unimportant 
from a therapeutic standpoint and patients may benefit from additional antioxidative therapy like N-
acetylcysteine or combined vitamin C and E. It was reported that N-acetylcysteine revealed positive 
effects after hematopoetic stem cell transplantation in three boys with an advanced stage of the 
CCALD [118]. However, there are no data on efficacy of antioxidative therapy from a larger series of 
patients. 
 
Lovastatin 12 
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14 
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Singh et al proposed lovastatin as a possible therapeutic agent. They showed normalization of 
VLCFA levels by lovastatin in cultured skin fibroblasts and X-ALD patients [119-121]. The molecular 
mechanism may be a stimulation of ABCD2 expression induced by reduction of the intracellular 
cholesterol content [122]. It is hypothesized that lovastatin additionally may have a favorable effect on 
the inflammatory response seen in the pathogenesis of cerebral ALD due to its capacity to abolish the 
cytokine-induced increase of nitric oxide synthase [123,124]. However in X-ALD fibroblasts cultured in 
cholesterol-free medium the decrease in 26:0 VLCFA is offset by an increase of 26:1, resulting in an 
unaltered total VLCFA pool [125]. It is therefore unclear, whether 26:0 reduction through cholesterol 
lowering is a feasible therapeutic approach. The clinical efficacy of lovastatin therapy in X-ALD 
patients remains to be proven. 
 
Gene therapy 24 
25 
26 
27 
Benhamida et al. demonstrated the correction of VLCFA levels in X-ALD CD34+ peripheral blood 
mobilized cells after transduction using an HIV-based vector driving ALD gene expression. 
Transplantation of transduced ALD CD34+ cells into NOD/SCID mice resulted in long-term expression 
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of ALD protein in monocytes/macrophages derived from engrafted stem cells [126]. Additionally, it 
was shown that cells derived from human CD34+ cells isolated from cord blood or peripheral blood 
migrate into the brain after infusion into immunodeficient mice and differentiate into perivascular and 
ramified microglia. The lentiviral gene transfer does not modify the differentiation of human CD34+ 
cells into microglia [52], and human CD34+ derived microglia would likely be attracted to the sites of 
neuronal damage [127]. The transplantation of such transduced cells is a candidate for future 
treatment of several hereditary CNS diseases including X-ALD. 
 
 
Key issues 
 
• Early diagnosis and timely initiation of therapy is crucial and can be achieved by screening of 12 
relatives of X-ALD patients. 
• Monitoring (and if applicable therapy) of adrenal function is mandatory. 14 
• LO therapy is recommended for all asymptomatic boys with X-ALD after the age of 1,5 years. 15 
These patients have to be monitored closely to discover cerebral involvement as early as 
possible. 
• LO therapy might not only be effective in asymptomatic patients, but also in neurodegenerative 18 
forms (e. g. AMN, symptomatic heterozygotes) and should therefore be offered to these 
patients in the personal opinion of the authors. 
• HCT has a relevant chance of success in early stages of CCALD (and probably ACALD as 21 
well). 
• Promising candidates for future drugs pharmacological up-regulation of other ABC transporter 23 
proteins, and gene therapy strategies, and lovastatin. 
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Figure 1: Pathological hallmarks of X-linked Adrenoleukodystrophy 
3 
4 
5 
A: Demyelination: Extensive confluent demyelination of the periventricular white matter with some 
sparing of U-fibres (HE staining)(left) and long spinal tracts (right). 
   
6 
7 
8 
B: Inflammation: Perivascular infiltration of inflammatory blood cells in brain tissue from a CCALD 
patient 
 
9 
10 
3. Storage: Lamellae and lipid profiles containing cholesterol esterified with VLCFA in adrenocortical 
cells (electron microcopy, J. Powers with permission) 
 11 
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Figure 2: MRI-pattern of X-ALD phenotypes 
A: Cerebral X-ALD: High signal in the splenium of the corpus callosum and adjacent parieto-occiptal 
white matter in T2 images (left); marginal contrast enhancement in T1W sequences (right).  
     
B: Long tract involvement in AMN: Severe thoracic cord atrophy and bilateral pyramidal tract 
involvement in the internal capsule level in an adult AMN patient in axial T1 (left) and T2 weighted 
images (right) 
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Figure 3. A. Kaplan-Meier estimate of survival for cerebral X-linked adrenoleukodystrophy following 
related (solid line, n=42) and unrelated donor (dashed line, n=52) hematopoietic cell transplantation. 
Ticks on probability lines indicate dates of censoring at last follow-up. 
Fig. 3. B.  Kaplan-Meier estimate of survival for cerebral X-linked adrenoleukodystrophy following 
hematopoietic cell transplantation by neurological deficit and MRI severity. Solid line indicates 
patients with mild neurological abnormalities ((clinical and brain MRI); n=25). Dashed line indicates 
patients with more severe neurological abnormalities (n=37). Ticks on probability lines indicate dates 
of censoring at last follow-up.  
Originally published in Blood. Peters et al. Cerebral X-linked adrenoleukodystrophy: the international 
hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104(3):881-8. © the 
American Society of Hematology. 
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Reference annotations: 
Aubourg 1990 * The first report about successful HCT in X-ALD 
Mahmood 2007 **Retrospective survival analysis of CCALD patients with early cerebral involvement 
confirms efficacy of HCT done in this stage of in X-ALD  
Moser 1999 **Description of VLCFA levels in a huge series of patients and controls and 
consequences for reliability in diagnosis and screening 
Moser 2000**Description of brain MRI findings in X-ALD 
Moser 2007*** Up to date review about X-ALD 
Moser 2005*** Presents data about the effectiveness of LO therapy to reduce the risk of developing 
brain MRI abnormalities 
Peters 2004 *** The most comprehensive work about HCT in CCALD 
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